Proteonomix, Inc. (PROT.OB) a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products.
**Proteonomix, Inc. Plans European Investor Road Show
The company PROT recently announced that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.).
In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.
For more information about this company please visit http://www.proteonomix.com\
MedcoHealth Solutions Inc. (NYSE:MHS) is pioneering the world’s most advanced pharmacy(R) and its clinical research and innovations are part of Medco making medicine smarter(TM) for approximately 65 million members. With more than 20,000 employees dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2009 revenues of nearly $60 billion, Medco ranks 35th on the Fortune 500 list and is named among the world’s most innovative, most admired and most trustworthy companies.
**Medco Health Solutions, Inc. and United BioSource Corporation (UBC) announced a definitive agreement under which Medco will acquire closely held UBC in an all-cash transaction valued at approximately $730 million.
The combination of America’s leading advanced pharmacy with one of the world’s most respected sources of post-approval drug and device research extends MHS core capabilities in data analytics and research to further accelerate pharmaceutical knowledge - advancing patient safety and furthering evidence-based medicine.
Upon closing the transaction, UBC would become a wholly-owned subsidiary of Medco that will be run independently from Medco’s core business to ensure compliance with contractual requirements and client expectations.
For more information about this company please visit http://www.medcohealth.com
Varian Medical Systems, Inc. (NYSE:VAR) is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world.
**Varian Medical Systems Establishes Radiotherapy Training Center in Mumbai, India
The company VAR recently has established its first education center in India to train medical physicists and technologists working on the company’s advanced cancer treatment systems.
The center in Mumbai, equipped with 16 planning system workstations and the VERT training system for radiotherapy treatment simulations, will enable the country’s growing number of radiotherapists and medical physicists to train without having to travel overseas.
The official opening, which was attended by Kanta Chokkra, president of the Association of Medical Physicists of India, was carried out by Kolleen Kennedy, Varian’s VP Customer Support Services.
For more information about this company please visit http://www.varian.com
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
PROTcrweselect0905
